9.07
price down icon1.31%   -0.12
after-market Handel nachbörslich: 9.25 0.18 +1.98%
loading
Schlusskurs vom Vortag:
$9.19
Offen:
$9.18
24-Stunden-Volumen:
1.03M
Relative Volume:
0.71
Marktkapitalisierung:
$1.23B
Einnahmen:
$175.51M
Nettoeinkommen (Verlust:
$-78.02M
KGV:
-17.11
EPS:
-0.53
Netto-Cashflow:
$-34.18M
1W Leistung:
+0.00%
1M Leistung:
+12.67%
6M Leistung:
+13.38%
1J Leistung:
+63.13%
1-Tages-Spanne:
Value
$9.035
$9.36
1-Wochen-Bereich:
Value
$8.55
$9.36
52-Wochen-Spanne:
Value
$5.195
$10.67

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name
Firmenname
Aurinia Pharmaceuticals Inc
Name
Telefon
250-744-2487
Name
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Name
Mitarbeiter
300
Name
Twitter
@AuriniaPharma
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
AUPH's Discussions on Twitter

Vergleichen Sie AUPH mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AUPH
Aurinia Pharmaceuticals Inc
9.07 1.20B 175.51M -78.02M -34.18M -0.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-11-04 Herabstufung Oppenheimer Outperform → Perform
2022-05-05 Fortgesetzt Cantor Fitzgerald Overweight
2021-12-10 Hochstufung Oppenheimer Perform → Outperform
2021-10-28 Herabstufung Oppenheimer Outperform → Perform
2021-01-25 Bestätigt H.C. Wainwright Buy
2020-11-03 Bestätigt H.C. Wainwright Buy
2020-06-17 Eingeleitet BTIG Research Buy
2020-05-05 Eingeleitet Cowen Outperform
2020-01-10 Eingeleitet Jefferies Buy
2019-12-16 Bestätigt H.C. Wainwright Buy
2018-03-16 Bestätigt Cantor Fitzgerald Overweight
2018-02-08 Eingeleitet RBC Capital Mkts Outperform
2017-10-30 Bestätigt H.C. Wainwright Buy
2017-05-18 Bestätigt H.C. Wainwright Buy
2017-04-11 Eingeleitet Cantor Fitzgerald Overweight
2017-03-22 Bestätigt FBR & Co. Outperform
2016-12-30 Bestätigt H.C. Wainwright Buy
2016-08-17 Bestätigt H.C. Wainwright Buy
2016-06-30 Eingeleitet H.C. Wainwright Buy
2015-05-08 Eingeleitet MLV & Co Buy
Alle ansehen

Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten

pulisher
Jul 23, 2025

What analysts say about Aurinia Pharmaceuticals Inc. stockDynamic profit expansion - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Aurinia Pharmaceuticals Inc. a good long term investmentUnmatched profit potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Aurinia Pharmaceuticals Inc. stock priceHigh-yield investments - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - BioSpace

Jul 22, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals to Announce Q2 2025 Financial Results - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals: LUPKYNIS Growth and AUR200 Pipeline Fuel Long-Term Value - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting - Yahoo.co

Jul 22, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough investment results - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

(AUPH) Technical Data - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 18, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) Delivers Shareholders Favorable 52% Return Over 1 Year, Surging 5.5% in the Last Week Alone - 富途牛牛

Jul 18, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo

Jul 17, 2025
pulisher
Jul 15, 2025

What makes Aurinia Pharmaceuticals Inc. stock price move sharplyDaily Breakout Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Aurinia Pharmaceuticals Inc. stock performs during market volatilityFree Stock Investment Discussion Area - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Aurinia Pharmaceuticals Inc. stock attracts strong analyst attentionReal Trader Insights - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

How did AUPH's Q3 2024 earnings surprise impact short-term traders? - AInvest

Jul 10, 2025
pulisher
Jul 09, 2025

Trading (AUPH) With Integrated Risk Controls - news.stocktradersdaily.com

Jul 09, 2025
pulisher
Jul 08, 2025

Wheat from chaff in BAFF: APRIL’s advent for Aurinia? - BioWorld MedTech

Jul 08, 2025
pulisher
Jul 07, 2025

The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity (NASDAQ:AUPH) - Seeking Alpha

Jul 07, 2025
pulisher
Jul 06, 2025

Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results - MSN

Jul 06, 2025
pulisher
Jul 02, 2025

Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - Nasdaq

Jul 02, 2025
pulisher
Jul 02, 2025

Implied Volatility Surging For Aurinia Pharmaceuticals Stock Options - Barchart.com

Jul 02, 2025
pulisher
Jul 01, 2025

Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH) - The Globe and Mail

Jul 01, 2025
pulisher
Jun 30, 2025

Aurinia’s aritinercept shows promising results in phase 1 study - Investing.com

Jun 30, 2025
pulisher
Jun 30, 2025

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) - New Castle News

Jun 30, 2025
pulisher
Jun 29, 2025

(AUPH) Trading Report - news.stocktradersdaily.com

Jun 29, 2025
pulisher
Jun 27, 2025

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? - Yahoo Finance

Jun 27, 2025
pulisher
Jun 26, 2025

Aurinia shares rise ahead of key autoimmune therapy data - Proactive financial news

Jun 26, 2025
pulisher
Jun 21, 2025

Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 50%, as stock drops 5.0% this past week - simplywall.st

Jun 21, 2025
pulisher
Jun 15, 2025

With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance

Jun 15, 2025
pulisher
Jun 12, 2025

Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA

Jun 12, 2025

Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Aurinia Pharmaceuticals Inc-Aktie (AUPH) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Greenleaf Peter
Chief Executive Officer
Mar 03 '25
Sale
8.00
195,593
1,564,744
1,953,892
Greenleaf Peter
Chief Executive Officer
Mar 04 '25
Sale
7.92
164,947
1,306,380
1,788,945
Keenan Greg
Chief Medical Officer
Mar 03 '25
Sale
8.00
12,239
97,912
161,789
Miller Joseph M
Chief Financial Officer
Mar 03 '25
Sale
8.00
61,859
494,872
633,515
Miller Joseph M
Chief Financial Officer
Mar 04 '25
Sale
7.92
56,154
444,740
577,361
Robertson Stephen P.
EVP, General Counsel
Mar 03 '25
Sale
8.00
64,872
518,976
566,883
Robertson Stephen P.
EVP, General Counsel
Mar 04 '25
Sale
7.92
57,607
456,247
509,276
Donley Matthew Maxwell
Chief Operating Officer
Mar 03 '25
Sale
8.00
65,902
527,216
739,456
Donley Matthew Maxwell
Chief Operating Officer
Mar 04 '25
Sale
7.92
58,991
467,209
680,465
TANG KEVIN
Director
Mar 04 '25
Buy
7.96
748,038
5,953,304
10,029,500
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Kapitalisierung:     |  Volumen (24h):